Cerulean Pharma Inc. is a clinical-stage, oncology-focused company applying its tumor targeting platform to develop therapies. The Companys nanoparticle-drug conjugate product candidates consist of polymers that are covalently linked to anti-cancer therapeutics, or payloads. Its lead product candidate, CRLX101, is in Phase II clinical development and can address cancer therapies. CRLX101 is designed to be a dual inhibitor of topoisomerase 1 and hypoxia-inducible factor-1 alpha (commonly referred to as HIF-1alpha). Its second product candidate, CRLX301, is a nanopharmaceutical with docetaxel, a microtubule stabilizer, as its anti-cancer payload. CRLX301 is designed to act as a tubulin inhibitor. The Companys ribonucleic acid (RNA) delivery program has produced a variety of RNA-containing NDCs that can overcome the challenges of RNA administration.